1.
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 t...
by Zhu, Feng-Cai, MSc
The Lancet (British edition), 2013, Vol.381 (9882), p.2024-2032
2.
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-...
by Zhu, Feng-Cai, MSc
The Lancet (British edition), 2015, Vol.385 (9984), p.2272-2279
3.
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
by Zhu, Feng-Cai, MSc
The Lancet (British edition), 2010, Vol.376 (9744), p.895-902
4.
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-contro...
by Zhu, Feng-Cai, MSc
The Lancet (British edition), 2016, Vol.389 (10069), p.621-628
5.
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
by Liang, Xiao-Feng, MD
The Lancet (British edition), 2010, Vol.375 (9708), p.56-66
6.
Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial
by Zhu, Feng-Cai, MSc
The Lancet (British edition), 2013, Vol.381 (9871), p.1037-1045
7.
Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial
by Zeng, Ming, PhD
The Lancet (British edition), 2015, Vol.386 (10002), p.1457-1464
